Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Oncology

Prevalence

56.0 / 100K

Incidence

19.6 / 100K/yr

18 drugs in development·4 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(17)

Drug	Company
Bleomycin Sulfate	Cosmos Health Inc. (COSM)
Bleomycin Sulfate	PTC THERAPEUTICS, INC. (PTCT)
Brentuximab Vedotin	AXIM BIOTECHNOLOGIES, INC. (AXIM)
Brentuximab Vedotin	Cosmos Health Inc. (COSM)
Dacarbazine	Cosmos Health Inc. (COSM)
Dacarbazine	AXIM BIOTECHNOLOGIES, INC. (AXIM)
Etoposide	Cosmos Health Inc. (COSM)
Etoposide	AXIM BIOTECHNOLOGIES, INC. (AXIM)
Etoposide Phosphate	AXIM BIOTECHNOLOGIES, INC. (AXIM)
Etoposide Phosphate	Cosmos Health Inc. (COSM)
Etoposide Phosphate	PTC THERAPEUTICS, INC. (PTCT)
Procarbazine Hydrochloride	PTC THERAPEUTICS, INC. (PTCT)
Procarbazine Hydrochloride	Cosmos Health Inc. (COSM)
Vinblastine Sulfate	Cosmos Health Inc. (COSM)
Vinblastine Sulfate	PTC THERAPEUTICS, INC. (PTCT)
Vincristine Sulfate	PTC THERAPEUTICS, INC. (PTCT)
Vincristine Sulfate	Cosmos Health Inc. (COSM)

Unknown(1)

Drug	Company
Bleomycin Sulfate	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 18 drugs in development for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 across 4 companies.

There are 1 clinical trial targeting Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 tracked by BioSniper.

The estimated prevalence of Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 is approximately 56.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.